EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities

Vinita Balakrishna Pai iD, Milap Chand Nahata

Pharmaceutics · 19.01.2026 · 18 (1) · 126

DOI: 10.3390/pharmaceutics18010126 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 19.01.2026. Verfasst von Vinita Balakrishna Pai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many commercially available medications are often unapproved or unavailable in suitable dosage forms for specific patient populations, particularly infants and children. This necessitates the use of extemporaneously compounded formulations to deliver individualized doses based on body weight or body surface area, and when a medication is unavailable at an appropriate concentration or contains excipients potentially unsafe for certain patients. Extemporaneous compounding is required for oral liquids when patients are unable to swallow tablets or capsules. It is also needed for topical preparations and sterile dosage forms when commercial products are unavailable. Across regions, practices follow national pharmacopeial standards for both sterile and non-sterile compounding. Stability factors influencing the safety and efficacy of compounded formulations must be carefully considered when assigning appropriate beyond-use dates. While stability information is available for some medications in monographs, peer-reviewed literature, prescribing information, and investigator’s brochures, such data is often lacking for many compounded preparations. Emerging extemporaneous formulations—such as orodispersible films, nanoparticle systems, and 3D-printed compounds—offer potential advantages over traditional compounded formulations but present unique challenges to widespread implementation. Despite the justified clinical need for extemporaneous compounding, significant barriers remain, including limited access to medications, insufficient compounding expertise or resources, gaps in pharmacokinetic and safety data, and regulatory constraints. This review critically appraises the current state of extemporaneous compounding—drawing primarily on the United States of America frameworks—and highlights its continued necessity, associated challenges, and pragmatic solutions for advancing personalized pharmacotherapy across pediatric age groups worldwide.

Schlagwörter

Stichwörter der Autor:innen

compoundingextemporaneous formulationspediatricspersonalized medicine

Autor:innen und Institutionen

  • Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
  • Institute of Therapeutic Innovations and Outcomes, Colleges of Pharmacy and Medicine, The Ohio State University, Columbus, OH 43210, USA.

ORCID-Profile: Vinita Balakrishna Pai

Zitieren

APA

Pai, V. B., & Nahata, M. C. (2026). Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities. Pharmaceutics, 18(1), 126. https://doi.org/10.3390/pharmaceutics18010126

Vancouver

Pai VB, Nahata MC. Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities. Pharmaceutics. 2026;18(1):126. doi:10.3390/pharmaceutics18010126

BibTeX
@article{Pai2026,
  author = {Pai, Vinita Balakrishna and Nahata, Milap Chand},
  title = {Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {126},
  doi = {10.3390/pharmaceutics18010126}
}
Kostenlos starten →